In this study, it was found that systemic administration of Agomir-186-3p could significantly reduce glycolysis and drug resistance in breast cancer cells, and that miR-186-3p and EREG were negatively correlated in human breast cancer samples, demonstrating the clinical correlation of the miR-186-3p/EREG axis in human breast cancer. This evidence concerns the gene EREG and breast carcinoma.